Add Android Authority on Google:
TL;DR
- HUAWEI has revealed a continuous glucose monitor in China.
- HUAWEI Sence G1 is the company’s first-ever Class III medical device.
- HUAWEI hasn’t shared details about availability but said it has been in development for over three years.
HUAWEI may have been nearly wiped out of international markets by sanctions imposed on it during the first tenure of US President Donald Trump, but it remains at the top of China’s leaderboard. Along with its innovations across slab phones, foldables, and laptops—including laptops with foldable screens —HUAWEI also offers a broad range of wearables, including ones that monitor blood pressure. So far, the lineup has only comprised smartwatches and fitness bands, but HUAWEI is now adding a health-centric utility in the form of a glucose monitor.
The HUAWEI Sence G1 is the company’s first continuous glucose monitor (CGM). The device works alongside other HUAWEI products, allowing users to view glucose levels on their phones, a smartwatch, or a HUAWEI fitness band. Besides monitoring a user’s glucose levels, the CGM will also alert them in case of any unusual spikes or dips.
Huawei CGM announcement, translated using Gemini.
While HUAWEI announced its entry into the segment in a Weibo post, it refrained from sharing details such as the monitor’s price, availability, or how long the sensor lasts before it must be replaced. Based on the image, we can see the CGM is about the size of a quarter-dollar coin and is ideally worn on the upper arm. Previous leaks cited by the Chinese outlet IT Home suggest that the CGM offers a lag time of 5 to 15 minutes and a MARD of less than 10%.
Meanwhile, in a separate post, HUAWEI’s VP Bruce Lee notes that the product has long been in development. In fact, it is one of the products that it has taken the longest to master. Lee mentions that the first time they tried it was three years ago, i.e., in December 2023, while teams working on it have been wearing it for much longer.
Beyond the development efforts, the long product launch cycle may have been due to the required medical certifications. VCBeat previously reported that China’s National Medical Products Administration approved the CGM on October 30 and that it was HUAWEI’s first Class III medical device.
Since the CGM is interdependent on other HUAWEI products, we might not see it launch globally. But we’ll let you know if that changes.
